Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

490
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
490
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

738
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
738
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis.

European journal of medicinal chemistry·2026
Same author

Functional correction of the untreatable <i>CFTR</i> 1717-1G>A mutation through mRNA- and sgRNA-optimized base editing.

Science translational medicine·2026
Same author

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions.

The European respiratory journal·2025
Same author

Modulators of anion channels and transporters as alternative therapeutic agents to normalize airway surface liquid in cystic fibrosis.

European journal of medicinal chemistry·2025
Same author

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

British journal of pharmacology·2025

Related Experiment Video

Updated: Jun 25, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K

Anoctamin pharmacology.

Michele Genovese1, Luis J V Galietta2

  • 1Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (NA), Italy.

Cell Calcium
|May 24, 2024
PubMed
Summary

Transmembrane protein 16 (TMEM16) family members, like TMEM16A and TMEM16F, have distinct functions. TMEM16A as a chloride channel and TMEM16F as a phospholipid scramblase offer potential therapeutic targets for various diseases.

Keywords:
Calcium signalingChannel inhibitorChannel potentiatorChloride channelDrug screening

More Related Videos

Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity
12:52

Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity

Published on: March 5, 2020

8.2K
Generation of Local CA1 &#947; Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.2K

Related Experiment Videos

Last Updated: Jun 25, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K
Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity
12:52

Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity

Published on: March 5, 2020

8.2K
Generation of Local CA1 &#947; Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.2K

Area of Science:

  • Membrane protein biology
  • Ion channel function
  • Lipid transport

Background:

  • The TMEM16 (anoctamin) family comprises ten membrane proteins with diverse roles.
  • TMEM16A functions as a calcium-activated chloride channel, crucial in epithelial and smooth muscle cells.
  • TMEM16F acts as a calcium-activated phospholipid scramblase, involved in cell signaling.

Purpose of the Study:

  • To explore the therapeutic potential of targeting TMEM16 proteins.
  • To differentiate the roles of TMEM16A and TMEM16F in physiological processes.
  • To assess the feasibility of modulating TMEM16 activity for disease treatment.

Main Methods:

  • Review of existing literature on TMEM16 protein family.
  • Analysis of TMEM16A expression and function in airway epithelial cells.
  • Investigation of TMEM16F's role in phospholipid scrambling.

Main Results:

  • TMEM16A modulation may benefit chronic obstructive respiratory diseases and hypertension.
  • TMEM16F inhibition shows potential as an anticoagulant and antiviral strategy.
  • The precise roles and therapeutic relevance of other TMEM16 family members remain under investigation.

Conclusions:

  • TMEM16A and TMEM16F represent distinct therapeutic targets with potential applications in respiratory diseases, hypertension, coagulation, and viral infections.
  • Further research is needed to clarify the roles of other TMEM16 proteins.
  • Targeting TMEM16 proteins offers promising avenues for novel pharmacological interventions.